Santen Pharmaceutical Co (SNPHY) Fair Value & Analysis
Healthcare · US · Market cap $3.9B · ISIN US80287P1003
What is Santen Pharmaceutical Co really worth?
Santen Pharmaceutical Co
SNPHY · US
A strong business, trading 29% below our fair value of $16.82.
Strengths
Risks
For context
Fair value as of: Aug 19, 2026
From 24 valuation models · updated 17 days ago
Share price +2.6% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict.
- A fairly wide model range ($11.34 to $21.34) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range $5.73 – $13.89 · fair‑value band $11.34 – $21.34 · the $11.95 price screens below the $16.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Santen Pharmaceutical Co (SNPHY) currently trades at $11.95, while our model-based Fair Value estimate is $16.82, implying the stock looks roughly 29.0% undervalued today. The Quality Score stands at 75/100 (high quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of $16.82 per share, and 18 of the 24 models we run sit above the $11.95 price. Bear case: the Asset-Based group reads lowest at $4.18, and 6 of the 24 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Santen Pharmaceutical Co generated revenue of $292B at a net margin of 12.8%. Revenue grew 4.7% year over year. It earns a return on equity of 12.9%. The balance sheet holds a net cash position of $81.2B. Fundamentals as of Aug 19, 2026
Our scenario range runs from $11.34 (bear case) to $21.34 (bull case); at $11.95, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 5% below its 52-week high and 26% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −18% fair-value upside, at 41%, SNPHY screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 24 models by family
Widest divergence: DCF Models ($16.82) versus Asset-Based ($4.18). Highest evidence: FCF DCF (81).
Notify me when SNPHY reaches fair value
Put SNPHY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 63
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally.
Full company description
Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval to treat allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension. Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a ß2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction. The company was founded in 1890 and is headquartered in Osaka, Japan.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Santen Pharmaceutical Co reported revenue of ¥309B in FY2026 versus ¥266B in FY2022, a compound +3.8%/yr. Reported net income was ¥39.6B in FY2026, compounding +9.8%/yr from FY2022.
of which total revenue +5.6 % · buybacks/dilution +1.9 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch SNPHY: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - General · 75 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,176 | $389.47 | −67% |
| Johnson & Johnson, JNJ | $265.77 | $169.04 | −36% |
| AbbVie Inc ABBV | $258.15 | $67.72 | −74% |
| Roche Holding RO | CHF 374.60 | CHF 306.54 | −18% |
| Merck & Co MRK | €131.98 | €101.38 | −23% |
| Novartis AG NOVN | CHF 123.74 | CHF 114.90 | −7% |
| Novo Nordisk A/S NOVOB | kr 295.50 | kr 409.46 | +39% |
| Amgen Inc AMGN | $436.99 | $252.02 | −42% |
| Gilead Sciences, Inc GILD | $148.86 | $146.50 | −2% |
| Pfizer Inc PFE | $28.02 | $24.87 | −11% |
Compare Santen Pharmaceutical Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Santen Pharmaceutical Co (SNPHY) overvalued or undervalued?
What is the fair value of SNPHY?
What is the quality score of SNPHY?
What is the revenue of Santen Pharmaceutical Co (SNPHY)?
What is the net profit margin of SNPHY?
Does Santen Pharmaceutical Co pay a dividend?
Watch Santen Pharmaceutical Co in the live analysis
One click puts Santen Pharmaceutical Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.